News from oncolytics biotech inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 26, 2015, 06:30 ET

Oncolytics Biotech® Inc. Presents at the 2015 Immune Checkpoint Inhibitors Meeting

CALGARY, March 26, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Giovanni...

Mar 25, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Ovarian Cancer

CALGARY, March 25, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology...

Mar 16, 2015, 18:08 ET

Oncolytics Biotech® Inc. Announces 2014 Year End Results

CALGARY, March 16, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced...

Mar 05, 2015, 06:30 ET

Oncolytics Biotech® Inc. Collaborators Present Preclinical Data on the Combination of REOLYSIN® and Radiotherapy in Melanoma at the Irish Association for Cancer Research Conference

CALGARY, March 5, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that an oral...

Mar 03, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer

CALGARY, March 3, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company...

Mar 02, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube

CALGARY, March 2, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company...

Feb 18, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study

CALGARY, Feb. 18, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has...

Feb 17, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer

CALGARY, Feb. 17, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology...

Feb 11, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer

CALGARY, Feb. 11, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology...

Feb 09, 2015, 06:30 ET

Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients

CALGARY, Feb. 9, 2015 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an...

Dec 22, 2014, 06:30 ET

Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers

CALGARY, Dec. 22, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted...

Dec 04, 2014, 06:30 ET

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference

CALGARY, Dec. 4, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation by the...

Dec 02, 2014, 06:30 ET

Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers

CALGARY, Dec. 2, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted...

Nov 18, 2014, 06:30 ET

Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference

CALGARY, Nov. 18, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will...

Nov 06, 2014, 06:30 ET

Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results

CALGARY, Nov. 6, 2014 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its...

Nov 04, 2014, 17:02 ET

Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency

CALGARY, Nov. 4, 2014 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that on...

Oct 24, 2014, 17:12 ET

Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution Agreement with Canaccord Genuity Inc.

CALGARY, Oct. 24, 2014 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it...

Oct 20, 2014, 17:32 ET

Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC

CALGARY, Oct. 20, 2014 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it...

Sep 16, 2014, 17:06 ET

Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

TORONTO, Sept. 16, 2014 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced overall and...

Sep 03, 2014, 14:48 ET

Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study

CALGARY, Sept. 3, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that patient...